Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up

We examined the benefits of the combination of anti-EGFR targeted treatment, cetuximab (CTX) or nimotuzumab (NTZ) and concurrent platinum-based chemoradiotherapy (CCRT) compared with CCRT alone in patients with stage II - IV(b) nasopharyngeal carcinoma (NPC). A total of 1,628 eligible patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Rui, Hua, Yi-Jun, Liu, You-Ping, Yang, Qi, Zhang, Yi-Nuan, Li, Ji-Bin, Li, Chao-Feng, Zou, Xiong, Yu, Tao, Cao, Jing-Yu, Zhang, Meng-Xia, Jiang, Rou, Sun, Rui, Mo, Hao-Yuan, Guo, Ling, Cao, Ka-Jia, Lin, Ai-Hua, Sun, Ying, Qian, Chao-Nan, Ma, Jun, Chen, Ming-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505063/
https://www.ncbi.nlm.nih.gov/pubmed/28740554
http://dx.doi.org/10.7150/thno.19710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505063/
https://www.ncbi.nlm.nih.gov/pubmed/28740554
http://dx.doi.org/10.7150/thno.19710

Ejemplares similares